Page last updated: 2024-12-07

4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide: a highly-selective, nonpeptide delta opioid receptor agonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123924
CHEMBL ID13470
CHEBI ID109556
SCHEMBL ID724753
MeSH IDM0234153

Synonyms (64)

Synonym
156727-74-1
4-[(4-allyl-2,5-dimethyl-piperazin-1-yl)-(3-methoxy-phenyl)-methyl]-n,n-diethyl-benzamide(snc-80)
(+)-4-[(alpha-r)-alpha-[2s,5r]-4-allyl[2,5-dimethyl-1-piperazinyl]-3-methoxybenzyl]-n,n-diethylbenzamide
4-((r)-((2r,5s)-4-allyl-2,5-dimethylpiperazin-1-yl)(3-methoxyphenyl)methyl)-n,n-diethylbenzamide
(+)-4-((alpha r)-((2s,5r)-4-allyl-2,5-dimethylpiperazin-1-yl)(3-methoxyphenyl)methyl)-n,n-diethylbenzamide
4-[(r)-((r)-4-(s)-allyl-2,5-dimethyl-piperazin-1-yl)-(3-methoxy-phenyl)-methyl]-n,n-diethyl-benzamide
3-[(4-allyl-2,5-dimethyl-piperazin-1-yl)-(4-diethylcarbamoyl-phenyl)-methyl]-benzoic acid
4-[(4-allyl-2,5-dimethyl-piperazin-1-yl)-(3-methoxy-phenyl)-methyl]-n,n-diethyl-benzamide (snc 80)
4-[(4-allyl-2,5-dimethyl-piperazin-1-yl)-(3-methoxy-phenyl)-methyl]-n,n-diethyl-benzamide
4-[(r)-(4-allyl-2,5-dimethyl-piperazin-1-yl)-(3-methoxy-phenyl)-methyl]-n,n-diethyl-benzamide
4-[(r)-[(2s,5r)-4-allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)-methyl]-n,n-diethylbenzamide
4-[(r)-((2s,5r)-4-allyl-2,5-dimethyl-piperazin-1-yl)-(3-methoxy-phenyl)-methyl]-n,n-diethyl-benzamide
4-((r)-((2s,5r)-4-allyl-2,5-dimethylpiperazin-1-yl)(3-methoxyphenyl)methyl)-n,n-diethylbenzamide
4-[(r)-((2r,5s)-4-allyl-2,5-dimethyl-piperazin-1-yl)-(3-methoxy-phenyl)-methyl]-n,n-diethyl-benzamide
bdbm50039029
HMS3266B16
BRD-K29546239-001-01-5
gtpl1611
nsc707484
nsc-707484
NCI60_038183
benzamide, 4-((2,5-dimethyl-4-(2-propenyl)-1-piperazinyl)(3-methoxyphenyl)methyl)-n,n-diethyl-, (2s-(1(s*),2alpha,5bet))-
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide
4-((2,5-dimethyl-4-(2-propenyl)-1-piperazinyl)(3-methoxyphenyl)methyl)-n,n-diethylbenzamide (2s-(1(s*),2alpha,5beta))-
snc 80
snc-80
tocris-0764
NCGC00024777-01
NCGC00024777-02
snc80
CHEBI:109556
(+)-4-[(alphar)-alpha-((2s,5r)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-n,n-diethylbenzamide
CHEMBL13470 ,
4-[(r)-[(2s,5r)-2,5-dimethyl-4-prop-2-enylpiperazin-1-yl]-(3-methoxyphenyl)methyl]-n,n-diethylbenzamide
NCGC00024777-03
dtxcid4025662
cas-156727-74-1
4-[(r)-[(2s,5r)-2,5-dimethyl-4-(2-propen-1-yl)-1-piperazinyl](3-methoxyphenyl)methyl]-n,n-diethylbenzamide
tox21_110925
dtxsid6045662 ,
unii-l842qb22sw
l842qb22sw ,
SCHEMBL724753
NCGC00024777-04
tox21_110925_1
(+)-4-[(?r)-?-((2s,5r)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-n,n-diethylbenzamide
AKOS024458637
sr-01000597706
SR-01000597706-1
AS-74938
4-[(r)-[(2s,5r)-2,5-dimethyl-4-(prop-2-en-1-yl)piperazin-1-yl](3-methoxyphenyl)methyl]-n,n-diethylbenzamide
J-009336
NCGC00024777-08
HMS3675H19
HY-101202
nih 10815
HMS3411H19
Q7391803
CS-0020978
4-((r)-((2s,5r)-2,5-dimethyl-4-(2-propen-1-yl)-1-piperazinyl)(3-methoxyphenyl)methyl)-n,n-diethylbenzamide
benzamide, 4-((r)-((2s,5r)-2,5-dimethyl-4-(2-propen-1-yl)-1-piperazinyl)(3-methoxyphenyl)methyl)-n,n-diethyl-
nih-10815
benzamide, 4-[(r)-[(2s,5r)-2,5-dimethyl-4-(2-propen-1-yl)-1-piperazinyl](3-methoxyphenyl)methyl]-n,n-diethyl-
AT27894

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"The present study examined the effects of SNC80 alone and in combination with the mu opioid agonists, morphine, butorphanol, and buprenorphine to determine whether SNC80 would enhance their antinociceptive effects."( Antinociceptive effects of the selective delta opioid agonist SNC80 alone and in combination with mu opioids in the squirrel monkey titration procedure.
Allen, RM; Dykstra, LA; Granger, AL; Rice, KC; Zhang, X, 2002
)
0.31

Bioavailability

ExcerptReferenceRelevance
"Due to low central nervous system (CNS) bioavailability of delta-opioid peptides, little is known about the effect of systemic administration of delta-opioid receptor ligands."( Spinal delta-opioid receptors mediate suppression of systemic SNC80 on excitability of the flexor reflex in normal and inflamed rat.
Cao, CQ; Dray, A; Hong, Y; Perkins, M, 2001
)
0.31
"02 L/h/kg) and poor bioavailability (<4%)."( Use of Freund's Complete Adjuvant (FCA) in inflammatory pain models: consequences on the metabolism and pharmacokinetics of the non-peptidic delta receptor agonist SNC80 in the rat.
Ducharme, J; Ducharme, MP; Lessard, E; Projean, D, 2007
)
0.34
" Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable delta agonist."( Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
Ajello, CW; Barker, WM; Belanger, S; Brogdon, BL; Cassel, JA; Christ, DD; Chu, GH; DeHaven, RN; DeHaven-Hudkins, DL; Derelanko, MJ; Dolle, RE; Feschenko, MS; Graczyk, TM; Gu, M; Koblish, M; Kutz, S; Le Bourdonnec, B; Leister, LK; Little, PJ; Smith, SA; Tuthill, PA; Wiant, DD; Windh, RT, 2008
)
0.35
"N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5859) and N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5747) are novel δ-opioid agonists that show good oral bioavailability and analgesic and antidepressive effects in the rat and represent potential drugs for chronic pain treatment."( δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization.
Dolle, RE; Gavériaux-Ruff, C; Kieffer, BL; Le Bourdonnec, B; Little, PJ; Nozaki, C; Reiss, D; Windh, RT, 2012
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"01 mg/kg) prior to cumulative doses of cocaine produced dose-dependent leftward shifts in the cocaine dose-response function."( Opioid enhancement of the discriminative stimulus effects of cocaine: evidence for involvement of mu and delta opioid receptors.
Rowlett, JK; Spealman, RD, 1998
)
0.3
" Pretreatment with a non-opioid receptor-selective dose (2 mg/kg) of NLXM produced a rightward shift in the dose-response function of EMD 61,753."( Effects of kappa opioids in the inflamed rat colon.
Gebhart, GF; Sengupta, JN; Snider, A; Su, X, 1999
)
0.3
" When compared to desipramine and fluoxetine, SNC80 was more active with a single dose whereas both desipramine and fluoxetine produced greater effects with subchronic dosing (3 doses)."( Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats.
Broom, DC; Folk, JE; Jutkiewicz, EM; Rice, KC; Traynor, JR; Woods, JH, 2002
)
0.31
" Using a mouse hot-plate test, dose-response relationships were first determined for all compounds individually and then for opioids co-administered with fixed doses of ketamine or dextromethorphan."( Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain.
Baker, AK; Hoffmann, VL; Meert, TF, 2002
)
0.31
" Using a mouse hot-plate test, dose-response relationships were first determined for all compounds individually and then for opioids co-administered with fixed doses of clonidine, ketamine or dextromethorphan."( Interactions of NMDA antagonists and an alpha 2 agonist with mu, delta and kappa opioids in an acute nociception assay.
Baker, AK; Hoffmann, VL; Meert, TF, 2002
)
0.31
" These two compounds also exhibited nanomolar potencies in dose-response experiments performed on wild-type, M262T, Y308H, and C328R CAM receptors."( Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors.
Befort, K; Décaillot, FM; Filliol, D; Kieffer, BL; Lazarus, LH; Schiller, PW; Schmidhammer, H; Tryoen-Tóth, P, 2005
)
0.33
" However, heroin, but not SNC-80 or U50488, significantly shifted the dose-response curve for THC discrimination to the left."( Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Goldberg, SR; Solinas, M, 2005
)
0.33
" We conclude that endogenous N/OFQ functionally opposes DOP transmission in substantia nigra reticulata and that NOP receptor antagonists might be used in combination with DOP receptor agonists to reduce their dosage while maintaining their full therapeutic efficacy."( Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
Ledonne, A; Mabrouk, OS; Mercuri, N; Morari, M; Viaro, R; Volta, M, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (52)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.62280.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency4.46680.004023.8416100.0000AID485290
phosphopantetheinyl transferaseBacillus subtilisPotency89.12510.141337.9142100.0000AID1490
SMAD family member 2Homo sapiens (human)Potency13.44810.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency13.44810.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency25.16180.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1468
AR proteinHomo sapiens (human)Potency31.67040.000221.22318,912.5098AID1259243; AID1259247
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.09640.01237.983543.2770AID1645841
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency10.89300.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency15.55970.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency13.86600.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.79020.000229.305416,493.5996AID743075
cytochrome P450 2D6Homo sapiens (human)Potency2.45450.00108.379861.1304AID1645840
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency30.106519.739145.978464.9432AID1159509
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency1.58490.00207.533739.8107AID891
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency3.98110.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency32.25430.000323.4451159.6830AID743065; AID743067
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency100.00000.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency32.55220.000627.21521,122.0200AID743202; AID743219
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.36130.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency5.01190.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency10.00000.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency5.01191.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorMus musculus (house mouse)IC50 (µMol)0.08420.00010.729810.0000AID148515; AID148517; AID383162; AID411135; AID450616
Delta-type opioid receptorMus musculus (house mouse)Ki0.00500.00000.53939.4000AID149074; AID56283; AID56424; AID692547; AID692548; AID776097
Delta-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)0.08790.00030.38877.0000AID149405; AID149505; AID149522
Delta-type opioid receptorRattus norvegicus (Norway rat)Ki0.00180.00000.60689.2330AID1456282; AID149649; AID149787; AID149799; AID149928; AID1901075
Kappa-type opioid receptorMus musculus (house mouse)Ki2.04900.00030.35942.7500AID148317; AID776095
Mu-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)4.77220.00010.887410.0000AID151300; AID151303; AID151443
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki1.56850.00000.38458.6000AID138708; AID141653; AID149284; AID151151; AID151742; AID151755; AID151890; AID152374
Kappa-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)3.60100.00050.36987.0000AID450618
Kappa-type opioid receptorRattus norvegicus (Norway rat)Ki3.53500.00000.18683.9500AID148460
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)1.80830.00010.813310.0000AID148355; AID148360; AID150819
Mu-type opioid receptorHomo sapiens (human)Ki0.82600.00000.419710.0000AID152075; AID444089
Delta-type opioid receptorHomo sapiens (human)IC50 (µMol)0.00860.00020.75218.0140AID148076; AID148084; AID148085; AID148086; AID148087; AID148088; AID148089
Delta-type opioid receptorHomo sapiens (human)Ki0.00140.00000.59789.9300AID1185659; AID148241; AID323570; AID386572; AID444088
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)3.28000.00030.71237.0700AID148565; AID148674; AID149405; AID260586
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Ki7.61750.00000.20186.4240AID149284; AID149423
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)2.48000.00001.201110.0000AID147858; AID147864
Kappa-type opioid receptorHomo sapiens (human)Ki3.74630.00000.362410.0000AID444090; AID95358; AID95359
Mu-type opioid receptorMus musculus (house mouse)IC50 (µMol)6.06600.00081.699210.0000AID450617
Mu-type opioid receptorMus musculus (house mouse)Ki0.86930.00000.12281.3000AID151151; AID692547
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)10.00000.00020.660310.0000AID260585
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.00120.00000.338510.0000AID1185659
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorRattus norvegicus (Norway rat)EC50 (µMol)0.16600.00050.36496.9000AID441378
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)0.00010.00000.32639.4000AID1137721
Delta-type opioid receptorHomo sapiens (human)EC50 (µMol)0.06670.00000.43328.3000AID1137717; AID1137723; AID148060; AID148066; AID149613; AID1604699; AID1633372; AID1655381; AID270240; AID310356; AID386574; AID417158; AID424040; AID444093; AID636101; AID719296
Delta-type opioid receptorHomo sapiens (human)Kd0.62900.00040.51471.9800AID95203
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Kd0.62900.00211.44444.8940AID95210
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)5.26400.00000.22448.9900AID1137725
Kappa-type opioid receptorHomo sapiens (human)Kd0.62900.00000.06700.8300AID95203
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Kd0.49500.00000.72092.1420AID141494; AID141495; AID141496; AID141497
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Delta-type opioid receptorRattus norvegicus (Norway rat)Activity0.06000.00000.11931.2200AID310939
Delta-type opioid receptorHomo sapiens (human)ED500.02600.02601.33371.9800AID296736
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)ED500.62900.50900.56900.6290AID148548
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)Emax0.14300.05800.12740.1430AID148549; AID95205
Mu-type opioid receptorCavia porcellus (domestic guinea pig)ED500.58400.31701.11532.1420AID152215; AID152216
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Emax0.13470.12300.14830.1770AID138842; AID138846; AID152217; AID152218
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (174)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (38)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneKappa-type opioid receptorMus musculus (house mouse)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorMus musculus (house mouse)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (281)

Assay IDTitleYearJournalArticle
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID441378Agonist activity at rat delta opioid receptor expressed in rat C6 cells assessed as inhibition of forskolin-stimulated cAMP production after 30 mins by radioimmunoassay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.
AID151886In vitro radioligand binding assay, for inhibition of [3H]DAMGO (Tyr-D-Ala-Gly-(Me)-Phe-Gly-ol) binding to Opioid receptor mu 1 in rat brain membranes.1999Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.
AID1206647Intrinsic efficacy at human delta opioid receptor-1 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay2015Journal of medicinal chemistry, May-28, Volume: 58, Issue:10
Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.
AID1137715Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID151742Binding affinity by inhibition of [3H]DAMGO binding to Opioid receptor mu 1 from rat brain membranes2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
Synthesis and binding affinities of 4-diarylaminotropanes, a new class of delta opioid agonists.
AID233969Ratio of binding affinity of mu opioid receptor to that of delta opioid receptor2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.
AID151601Binding affinity at Opioid receptor mu 1 by displacement of [3H]DAMGO in rat brain membrane2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID148547Agonistic activity towards Opioid receptor kappa 1 was determined in [35S]GTP-gamma-S, binding assay in guinea pig caudate; na = not applicable2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID19938Maximal efficacy (Emax value)2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID149841Percent stimulation of [35S]GTP-gamma-S, binding by the compound in guinea pig caudate membranes for kappa opioid receptor selective condition2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
AID233684Selectivity ratio of the affinity for kappa and delta opioid receptors (Ki mu/Ki delta)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID386576Inhibition of human ERG channel in HEK293 cells by voltage-clamp method2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
AID148548Ability to stimulate binding to kappa-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 6 nM nor-binaltorphimine (nor-BNI)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID56424Binding affinity towards opioid Delta receptor using [3H]DADLE as radioligand1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID149423In vitro radioligand binding assay, for inhibition of [3H]U-69593 binding to Opioid receptor kappa 1, in guinea pig brain membranes.1999Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.
AID1901075Displacement of [3H]-DPDPE from DOR in rat brain membranes measured by competitive radioligand receptor binding assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Synthesis of 8-aminomorphans with high KOR affinity.
AID149928Inhibition of binding of [3H]-DPDPE to opioid receptor delta 1 from rat brain membrane.2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Piperazinyl benzamidines: synthesis and affinity for the delta opioid receptor.
AID231546Ratio of binding affinity towards mu opioid receptor by displacement of [3H]-DAMGO radioligand to that of delta opioid receptor by displacement of [3H]-DADLE radioligand2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
AID260588Permeability from apical to basolateral side of the Caco-2 cell membrane2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Highly potent and selective zwitterionic agonists of the delta-opioid receptor. Part 1.
AID150048Ability to stimulate binding to delta-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 20 nM naltrindole (NTI); NS= no stimulation2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID383163Displacement of [3H]U69593 from kappa opioid receptor in guinea pig cerebellum2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.
AID229954Relative affinity mu and delta opioid receptors of rat brain1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.
AID1456295Displacement of [3H]DADLE from delta opioid receptor in rat brain at 100 nM after 60 mins by liquid scintillation counting method relative to control2017Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8
Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.
AID149721Agonistic activity towards Opioid receptor mu 1 was determined in [35S]GTP-gamma-S, binding assay in guinea pig caudate; na = not applicable2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID152218Ability to stimulate binding to mu-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 6000 nM CTAP2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID56286[35S]GTP-gamma-S, induced maximal stimulation ( E max ) Delta opioid receptor in guinea pig caudate membranes blocked with 20 nM NTI; No stimulation1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID149768Apparent binding affinity of compound was determined towards opioid receptor delta 1 in [35S]GTP-gamma-S, binding assay in guinea pig caudate; na = not applicable2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID1240995Agonist activity at delta opioid receptor in mouse vas deferens assessed as reduction in electric field stimulation-induced twitch contractions amplitude in presence of 1 nM natrindole2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Novel diazabicycloalkane delta opioid agonists.
AID141653Binding affinity towards opioid Mu receptor using [3H]DAMGO as radioligand1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID139933Potency in the Mouse vas deferens (MVD) functional assay was determined in vivo1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using AlCl3-promoted aminolysis.
AID310356Agonist activity at human delta opioid receptor expressed in CHO cell membrane by [35S]GTP-gamma-S binding assay2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC.
AID776090Agonist activity at delta opioid receptor in mouse vas deferens assessed as inhibition of electrically-stimulated muscle contraction in presence of CTAP2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons.
AID23342The % of compound remaining in rat liver microsomes at 10 uM concentration after 1 hr incubation.2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.
AID149730Agonistic activity for Opioid receptor mu 1 as inhibitory activity towards electrically stimulated guinea pig ileum1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.
AID444093Agonist activity at human delta opioid receptor by [35S]GTPgammaS binding assay2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent models.
AID150055Percent stimulation of [35S]GTP-gamma-S, binding by the compound in guinea pig caudate membranes for delta opioid receptor selective condition2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
AID450617Displacement of [3H]DAMGO from mouse mu opioid receptor expressed in HEK293 cells by liquid scintillation counting2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.
AID1240988Intrinsic agonist activity at delta opioid receptor in mouse/rat NG108-15 cells assessed as increase in ERK1/2 phosphorylation at 10 nM pre-treated with 500 nM opioid antagonist naloxone for 5 mins followed by compound exposure for 20 mins by Western blot2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Novel diazabicycloalkane delta opioid agonists.
AID138841[35S]GTP-gamma-S, induced maximal stimulation ( E max ) against Mu opioid receptor in guinea pig caudate membranes blocked with 6000 nM CTAP1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID138846[35S]GTP-gamma-S, induced maximal stimulation ( E max )against Mu opioid receptor in guinea pig caudate membranes in unblocked condition1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID1240994Agonist activity at delta opioid receptor in mouse vas deferens assessed as reduction in electric field stimulation-induced twitch contractions amplitude2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Novel diazabicycloalkane delta opioid agonists.
AID636101Agonist activity at human recombinant delta opioid receptor expressed in human HEK293 cells by [35S]GTPgammaS binding assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis of quinolinomorphinan-4-ol derivatives as δ opioid receptor agonists.
AID1240986Intrinsic agonist activity at delta opioid receptor in mouse/rat NG108-15 cells assessed as increase in ERK1/2 phosphorylation by Western blot method2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Novel diazabicycloalkane delta opioid agonists.
AID148196Percent stimulation of [35S]GTP-gamma-S, binding by the compound in guinea pig caudate membranes for mu opioid receptor selective condition2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
AID152215Ability to stimulate binding to mu-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes under unblocked condition2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID441377Agonist activity at rat delta opioid receptor expressed in rat C6 cells assessed as inhibition of forskolin-stimulated cAMP production at 1 uM after 30 mins by radioimmunoassay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.
AID95358Binding affinity towards opioid kappa receptor using [3H]U-69593 as radioligand1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID719295Agonist activity at human delta opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting relative to untreated control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC.
AID147858Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.
AID1137721Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID233757IC50 ratio of mu to delta receptor1999Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.
AID233734Binding affinity ratio between kappa and delta receptor was determined2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID270240Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding2006Journal of medicinal chemistry, Sep-07, Volume: 49, Issue:18
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine.
AID1206653Binding affinity to human delta opioid receptor expressed in CHO cells after 1 hr by [35S]GTPgammaS binding assay2015Journal of medicinal chemistry, May-28, Volume: 58, Issue:10
Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.
AID148089Inhibition of binding of [3H]- -naltrindole (0.15 nM) to membranes from CHO cells expressing Opioid receptor delta 11999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using AlCl3-promoted aminolysis.
AID776097Displacement of [3H]DPDPE from mouse brain delta opioid receptor by scintillation counting analysis2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons.
AID234380Selectivity ratio of IC50 of mu opioid receptor to that of delta opioid receptor2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.
AID148360Binding affinity on cloned opioid receptor mu 1 in human HEK293S cells using [125I]FK33824 as radioligand.2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.
AID148087Binding affinity for Opioid receptor delta 1 by the inhibition of binding of [3H]-p-DPDPE human cloned receptors.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
AID149724Emax value towards Opioid receptor mu 1 determined in [35S]GTP-gamma-S, binding assay in guinea pig caudate2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID450625Agonist activity at mouse delta opioid receptor expressed in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding at 10 uM after 90 mins by liquid scintillation counting relative to control2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.
AID129299Antinociceptive activity against acetic acid induced abdominal constriction model in mice by sc administration1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using AlCl3-promoted aminolysis.
AID1655381Agonist activity at human DOR expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Developing Cyclic Opioid Analogues: Fluorescently Labeled Bioconjugates of Biphalin.
AID386575Displacement of [3H]diprenorphine from human kappa opioid receptor in CHO cells at 10 uM2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
AID151443Inhibition of radioligand [3H]DAMGO binding to rat brain Opioid receptor mu 1 using 100 nM DAMGO1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80)
AID1185659Displacement of [3H]-deltorphine from human delta opioid receptor expressed in CHO-K1 cells by scintillation counting analysis2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted κ-opioid receptor agonists.
AID383161Displacement of [3H]DAMGO from mu opioid receptor in ICR mouse whole brain2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.
AID224561Binding affinity towards mu opioid receptor using [3H]- -DAMGO (1.5 nM) as radioligand in rat brain membranes1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using AlCl3-promoted aminolysis.
AID148355Binding affinity against cloned human Opioid receptor mu 1 using [125I]FK33824 as radioligand2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.
AID141495Binding affinity against Mu opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 6000 nM CTAP1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID719296Agonist activity at human delta opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC.
AID138845[35S]GTP-gamma-S, induced maximal stimulation ( E max )against Mu opioid receptor in guinea pig caudate membranes in unblocked condition1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID1206659Intrinsic efficacy at human delta opioid receptor expressed in F1pIn CHO cells assessed as ERK1/2 phosphorylation2015Journal of medicinal chemistry, May-28, Volume: 58, Issue:10
Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.
AID141497Binding affinity against Mu opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes in unblocked condition1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID229970IC50 ratio on Mu receptor of GPI to the delta receptor MVD1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80)
AID148076Binding affinity against human opioid receptor delta 1 using [125I]-[D-Ala2]-deltorphin II as radioligand2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.
AID223052Percent stimulation of [35S]GTP-gamma-S, binding by the compound in guinea pig caudate membranes for unblocked condition2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
AID444088Displacement of [125I]-[D-Ala2]deltorphin 2 from human cloned delta opioid receptor2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent models.
AID1254732Antitrichomonal activity against Trichomonas vaginalis after 48 hrs by invert microscope analysis2015Bioorganic & medicinal chemistry letters, Nov-01, Volume: 25, Issue:21
Investigation of 7-benzylidenenaltrexone derivatives as a novel structural antitrichomonal lead compound.
AID152216Ability to stimulate binding to mu-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 6000 nM CTAP2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID148066Effective concentration as delta agonist potency using [35S]GTP-gamma-S binding assay.2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.
AID95205[35S]GTP-gamma-S, induced maximal stimulation ( E max )against Kappa opioid receptor in guinea pig caudate membranes blocked with 6 nM nor-BNI1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID231904Ratio between the IC50 values of mu and delta receptors1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist.
AID95204[35S]GTP-gamma-S, induced maximal stimulation ( E max )against Kappa opioid receptor in guinea pig caudate membranes blocked with 6 nM nor-BNI1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID1206651Intrinsic efficacy at human delta opioid receptor expressed in CHO cells after 1 hr by [35S]GTPgammaS binding assay2015Journal of medicinal chemistry, May-28, Volume: 58, Issue:10
Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.
AID444089Displacement of [125I]FK33824 from human cloned mu opioid receptor2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent models.
AID232232Selectivity given as ratio of kappa receptor to delta receptor2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID450616Displacement of [3H]DPDPE from mouse delta opioid receptor expressed in HEK293 cells by liquid scintillation counting2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.
AID229953Relative affinity for mouse vas deferens (mu receptor) and guinea pig ileum (delta receptor)1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.
AID1137724Agonist activity at human delta opioid receptor expressed in HEK293 cells by CellKey method relative to SNC802014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID149284Compound was evaluated for binding affinity towards Opioid receptor kappa 1 by displacement of [3H]U-69593 radioligand2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
AID424040Agonist activity at human recombinant delta opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
Design and synthesis of novel delta opioid receptor agonists and their pharmacologies.
AID151890Inhibition of binding of [3H]DAMGO to opioid receptor mu 1 from rat brain membrane.2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Piperazinyl benzamidines: synthesis and affinity for the delta opioid receptor.
AID1137723Agonist activity at human delta opioid receptor expressed in HEK293 cells by CellKey method2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID148085Binding affinity was measured against cloned human Opioid receptor delta 1 (wild-type,Wt)1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID150819Binding affinity for micro receptors by the inhibition of binding of [3H]DAMGO to Opioid receptor mu 1 in human cloned receptors.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
AID30005Metabolic stability at a concentration of 100 uM in rat liver microsomes after 1 hr incubation2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.
AID450622Selectivity ratio of IC50 for mouse mu opioid receptor to IC50 for mouse delta opioid receptor2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.
AID1137717Agonist activity at human delta opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID131255Maximum efficacy in Mouse vas deferens (MVD) functional assay was determined in vivo at a compound concentration of 10E-10 to 10E-51999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using AlCl3-promoted aminolysis.
AID84870Maximum efficacy in the Hamster vas deferens (HVD) functional assay was determined in vivo at a compound concentration of 10E-10 to 10E-51999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using AlCl3-promoted aminolysis.
AID296735Agonist activity at human delta opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay relative to SNC802007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorph
AID231108Ratio of binding affinities (Mu/Delta)1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID56287[35S]GTP-gamma-S, induced maximal stimulation ( E max ) Delta opioid receptor in guinea pig caudate membranes blocked with 20 nM NTI; No stimulation1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID148565Inhibition of [3H]- U69,593 binding to Guinea pig Opioid receptor kappa 11996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.
AID141494Binding affinity against Mu opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 6000 nM CTAP1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID147901Apparent binding affinity of compound was determined by antagonism towards Opioid receptor mu 1 in [35S]GTP-gamma-S, binding assay in guinea pig caudate; na = not applicable2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID260584Agonist activity at delta opioid receptor in mouse vas deferens2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Highly potent and selective zwitterionic agonists of the delta-opioid receptor. Part 1.
AID296736Agonist activity at human delta opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorph
AID152075Binding affinity for mu opioid receptor2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
N,N-dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective delta opioid agonists.
AID148517Agonist activity was evaluated in mouse vas deferens (MVD) preparations at Opioid receptor delta 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80)
AID1206649Binding affinity to human delta opioid receptor-1 expressed in CHO cells after 90 mins by beta-arrestin recruitment assay2015Journal of medicinal chemistry, May-28, Volume: 58, Issue:10
Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.
AID151755Compound was evaluated for binding affinity towards Opioid receptor mu 1 by displacement of [3H]-DAMGO radioligand2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
AID141645Evaluated for inhibition of [3H]DAMGO binding from mu receptor in rat brain membranes1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist.
AID149728Agonist activity using strips of guinea pig ileum longitudinal muscle myenteric plexus.1999Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.
AID228348Ki ratio of mu to delta receptor1999Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.
AID692548Displacement of [3H]-DPDPE from mouse DOR expressed in HEK293 cells2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.
AID1358136Agonist activity at human DOR expressed in African green monkey COS1 cell membranes assessed as stimulation of [35S]GTPgS binding at 10 uM by scintillation counting method2018European journal of medicinal chemistry, May-10, Volume: 151Synthesis of 7β-hydroxy-8-ketone opioid derivatives with antagonist activity at mu- and delta-opioid receptors.
AID1461556Antimicrobial activity against Trichomonas vaginalis after 48 hrs by neutral red staining based invert microscopic analysis2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.
AID776091Agonist activity at delta opioid receptor in mouse vas deferens assessed as inhibition of electrically-stimulated muscle contraction in presence of Naltrindole2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons.
AID149124Binding affinity at Opioid receptor kappa 1 by displacement of [3H]U-69593 in guinea pig brain membranes2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID148638In vitro antagonist activity against Opioid receptor delta 1 in the presence of 30 nM naltrindole, in a mouse vas deferens assay1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.
AID1456282Displacement of [3H]DADLE from delta opioid receptor in rat brain after 60 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8
Modulation of opioid receptor affinity and efficacy via N-substitution of 9β-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study.
AID231954Ratio of delta to that of mu opioid receptor affinity2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Piperazinyl benzamidines: synthesis and affinity for the delta opioid receptor.
AID1137722Agonist activity at human mu opioid receptor expressed in HEK293 cells by CellKey method relative to DAMDO2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID191944Percent stimulation of [35S]GTP-gamma-S, binding by the compound (10 uM)2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Probes for narcotic receptor-mediated phenomena. 27. Synthesis and pharmacological evaluation of selective delta-opioid receptor agonists from 4-[(alphaR)-alpha-(2S,5R)-4-substituted-2, 5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and t
AID149799Compound was evaluated for binding affinity towards Opioid receptor delta 1 by displacement of [3H]-DADLE radioligand2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
AID148088Binding inhibition of [3H]- -naltrindole (0.15 nM) to membranes in CHO cells expressing Opioid receptor delta 11999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using REM resin.
AID386573Displacement of [3H]diprenorphine from human mu opioid receptor in CHO cells at 10 uM2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
AID149922In vitro binding affinity to Opioid receptor delta 1 in rat brain membranes by [3H]DADLE (Tyr-D-Ala-Gly-Phe-D-Leu) displacement.1999Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.
AID386572Displacement of [3H]diprenorphine from human delta opioid receptor in CHO cells2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
AID149659Binding affinity at opioid receptor delta 1 by displacement of [3H]DADLE in rat brain membrane2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID1137720Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding relative to U695932014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID149649Affinity of [H]DADLE to the delta opioid receptor from rat brain2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID450618Displacement of [3H]U69593 from rat kappa opioid receptor expressed in HEK293 cells by liquid scintillation counting2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.
AID148072Emax value from 3-parameter logistic curve fits of percent stimulated [35S]GTP-gamma-S binding vs log(molar ligand).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.
AID1206657Binding affinity to human delta opioid receptor-1 expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 45 mins by time-resolved fluorescence assay2015Journal of medicinal chemistry, May-28, Volume: 58, Issue:10
Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.
AID1137725Agonist activity at human kappa opioid receptor expressed in HEK293 cells by CellKey method2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID149522Inhibition of radioligand [3H]DADLE binding to rat brain Opioid receptor delta 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80)
AID148660Tested for inhibition of binding of [3H]DADLE to mouse brain membranes depleted of mu binding sites by pretreatment with irreversible ligand BIT for delta opioid receptor1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist.
AID233685Selectivity ratio of the affinity for mu and delta opioid receptors (Ki mu/Ki delta)1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.
AID383162Displacement of [3H]DPDPE from delta opioid receptor in ICR mouse whole brain2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.
AID776095Displacement of [3H]U-69,593 from mouse brain kappa opioid receptor by scintillation counting analysis2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons.
AID224583Binding affinity towards mu opioid receptor using [3H]- -DAMGO (1.5 nM) as radioligand in rat brain membranes1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using REM resin.
AID231905Ratio between the IC50 values of mu and delta receptors; nd=not determined1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist.
AID1206661Binding affinity to human delta opioid receptor expressed in CHO cells assessed as ERK1/2 phosphorylation2015Journal of medicinal chemistry, May-28, Volume: 58, Issue:10
Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID417159Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding relative to basal level2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID95210Binding affinity against kappa opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 6 nM nor-BNI1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID149074Binding affinity against Opioid receptor delta 1 using [3H][D-Ala2, D-Leu5]-enkephalin as radioligand1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.
AID232233Selectivity given as ratio of mu receptor to delta receptor2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID151151Binding affinity against Opioid receptor mu 1 using [3H][D-Ala2, MePhe4, Gly-ol5]-enkephalin as radioligand1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.
AID147864Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.
AID148241Binding affinity for delta opioid receptor2004Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9
N,N-dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective delta opioid agonists.
AID228961Relative binding affinity to mu and delta opioid receptors1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
AID692547Displacement of [3H]-DPDPE from mouse MOR/DOR expressed in HEK293 cells2012ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8
Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.
AID30004Metabolic stability at a concentration of 10 uM in rat liver microsomes after 1 hr incubation2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.
AID1240987Toxicity in mouse/rat NG108-15 cells2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Novel diazabicycloalkane delta opioid agonists.
AID138842[35S]GTP-gamma-S, induced maximal stimulation ( E max ) against Mu opioid receptor in guinea pig caudate membranes blocked with 6000 nM CTAP1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID148561Binding affinity towards Opioid receptor kappa 1 using [3H]- U-69,593 (1.5 nM) as radioligand in guinea pig brain membranes1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using REM resin.
AID151303Inhibition of [3H]- DAMGO binding to Rat brain Opioid receptor mu 11996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.
AID231646Binding affinity ratio of kappa opioid receptor (guinea pig brain membranes) with respect to delta opioid receptor( rat brain membranes)1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
AID260589Ratio of permeability from apical to basolateral over basolateral to apical side of the Caco-2 cell membrane2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Highly potent and selective zwitterionic agonists of the delta-opioid receptor. Part 1.
AID1358135Agonist activity at human DOR expressed in African green monkey COS1 cell membranes assessed as stimulation of [35S]GTPgS binding at 1 uM by scintillation counting method2018European journal of medicinal chemistry, May-10, Volume: 151Synthesis of 7β-hydroxy-8-ketone opioid derivatives with antagonist activity at mu- and delta-opioid receptors.
AID148084Binding affinity on cloned opioid receptor delta 1 in human HEK293S cells using [125I]-[D-Ala2]-deltorphin II as radioligand.2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID151300Binding affinity was measured against Opioid receptor mu 1 using [3H]-DAMGO as radioligand.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor.
AID148515Agonist activity using electrically induced smooth muscle contraction of mouse vas deferens.1999Journal of medicinal chemistry, Dec-30, Volume: 42, Issue:26
Probes for narcotic receptor mediated phenomena. 26. Synthesis and biological evaluation of diarylmethylpiperazines and diarylmethylpiperidines as novel, nonpeptidic delta opioid receptor ligands.
AID30006The % of compound remaining in rat liver microsomes at 100 uM concentration after 1 hr incubation.2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.
AID138708Binding affinity towards opioid Mu receptor using [3H]DAMGO as radioligand1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID152217Ability to stimulate binding to mu-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes under unblocked condition2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID148060Agonist potency was measured using GTP gamma-[35S] binding assay2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.
AID776093Selectivity ratio of Ki for mouse brain kappa opioid receptor to Ki for mouse brain delta opioid receptor2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons.
AID182092Percent inhibition of SNC80 stimulated [35S]GTP-gamma-S, binding by the compound (10 uM)2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Probes for narcotic receptor-mediated phenomena. 27. Synthesis and pharmacological evaluation of selective delta-opioid receptor agonists from 4-[(alphaR)-alpha-(2S,5R)-4-substituted-2, 5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and t
AID231026Mu/delta inhibitory ratio of compound determined Rat brain receptors1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80)
AID1633372Agonist activity at human delta opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Cyclic Biphalin Analogues by Ruthenium-Catalyzed Ring Closing Metathesis:
AID95203Binding affinity against kappa opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes blocked with 6 nM nor-BNI1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID56283Binding affinity towards opioid Delta receptor using [3H]DADLE as radioligand1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID149509Binding affinity for Opioid receptor delta 1 by the inhibition of binding of [3H]DADAL in rat brain membranes.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
AID1240985Intrinsic agonist activity at delta opioid receptor in mouse/rat NG108-15 cells assessed as increase in ERK1/2 phosphorylation at 0.1 to 100 uM iincubated for 20 mins by Western blot method2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Novel diazabicycloalkane delta opioid agonists.
AID310938Agonist activity at rat delta opioid receptor expressed in C6 cells assessed as stimulation of [35S]GTP-gamma-S binding relative to BW373U862007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.
AID149505Inhibition of [3H]- DADLE binding to Rat brain Opioid receptor delta 11996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.
AID260585Agonist activity at mu opioid receptor in myenteric plexus muscle from guinea pig2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Highly potent and selective zwitterionic agonists of the delta-opioid receptor. Part 1.
AID78858Agonistic activity in Guinea Pig Ileum1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.
AID310939Displacement of [3H]naltrindole from rat delta opioid receptor expressed in C6 cells2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.
AID1206655Intrinsic efficacy at human delta opioid receptor-1 expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 45 mins by time-resolved fluorescence assay2015Journal of medicinal chemistry, May-28, Volume: 58, Issue:10
Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.
AID151428Binding affinity for Opioid receptor mu 1 by the inhibition of binding of [3H]DAMGO in rat brain membranes.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
AID1137712Displacement of [3H]U69593 from kappa opioid receptor in guinea pig cerebellum membrane2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID260590Effect on locomotor activity in mouse hyper locomotion model at 400 ug/kg, iv2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Highly potent and selective zwitterionic agonists of the delta-opioid receptor. Part 1.
AID417164Antagonist activity against human delta opioid receptor expressed in CHO cells assessed as inhibition of SNC80-stimulated [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID149931Inhibitory activity against Opioid receptor delta 1 in rat brain membranes using [3H]DADLE as a radioligand.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
Probes for narcotic receptor-mediated phenomena. 27. Synthesis and pharmacological evaluation of selective delta-opioid receptor agonists from 4-[(alphaR)-alpha-(2S,5R)-4-substituted-2, 5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamides and t
AID450624Agonist activity at FLAG-tagged delta opioid receptor expressed in HEK293 cells assessed as receptor down regulation at 10 uM by Bradford assay relative to control2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.
AID149111Apparent binding affinity of compound was determined by antagonism towards Opioid receptor kappa 1 in [35S]GTP-gamma-S, binding assay in guinea pig caudate; na = not applicable2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID776092Agonist activity at delta opioid receptor in mouse vas deferens assessed as inhibition of electrically-stimulated muscle contraction2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons.
AID138340Agonistic activity in Mouse Vas Deferens1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.
AID148460Affinity of [3H]U-69593 to opioid receptor kappa 1 from rat brain2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID1137719Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID148674Binding affinity for Opioid receptor kappa 1 by the inhibition of binding of [3H]U-69593 in guinea pig brain membranes.1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
AID1137726Agonist activity at human kappa opioid receptor expressed in HEK293 cells by CellKey method relative to (-)U50488H2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID149787Inhibition of [3H]DPDPE radioligand binding to rat opioid receptor delta 1 site from rat brain membranes2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
Synthesis and binding affinities of 4-diarylaminotropanes, a new class of delta opioid agonists.
AID1137716Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]-GTP[gammaS] binding relative to DAMDO2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID450623Selectivity ratio of IC50 for rat kappa opioid receptor to IC50 for mouse delta opioid receptor2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.
AID417158Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Syntheses of novel high affinity ligands for opioid receptors.
AID234379Selectivity ratio of IC50 of kappa opioid receptor to that of delta opioid receptor2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.
AID1137710Displacement of [3H]DAMGO from mu opioid receptor in mouse whole brain cerebellum membrane2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID224725Binding affinity ratio between mu and delta receptor was determined2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID148317Binding affinity against Opioid receptor kappa 1 using [3H]-U-69,593 as radioligand1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.
AID1604699Agonist activity at human DOR expressed in CHO cell membranes incubated for 1 hr by [35S]-GTPgammaS coupling assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Potent, Efficacious, and Stable Cyclic Opioid Peptides with Long Lasting Antinociceptive Effect after Peripheral Administration.
AID776096Displacement of [3H]DAMGO from mouse brain mu opioid receptor by scintillation counting analysis2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons.
AID323570Displacement of [3H]deltorphine 2 from human delta opioid receptor expressed in CHOK1 cells2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Synthesis and pharmacological evaluation of bicyclic SNC80 analogues with separated benzhydryl moiety.
AID444090Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent models.
AID141496Binding affinity against Mu opioid receptor using [35S]GTP-gamma-S, binding assay in guinea pig caudate membranes in unblocked condition1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID231547Ratio of binding affinity towards mu opioid receptor to that of delta opioid receptor2000Bioorganic & medicinal chemistry letters, May-15, Volume: 10, Issue:10
Synthesis and binding affinities of 4-diarylaminotropanes, a new class of delta opioid agonists.
AID1137714Selectivity ratio of Ki for guinea pig kappa opioid receptor to Ki for mouse delta opioid receptor2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID260586Agonist activity at kappa opioid receptor in myenteric plexus muscle from guinea pig2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Highly potent and selective zwitterionic agonists of the delta-opioid receptor. Part 1.
AID411135Displacement of [3H]DPDPE from delta opioid receptor in mouse whole brain without cerebellum2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Synthesis of a novel 6,14-epoxymorphinan derivative and its pharmacology.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID776094Selectivity ratio of Ki for mouse brain mu opioid receptor to Ki for mouse brain delta opioid receptor2013European journal of medicinal chemistry, Nov, Volume: 69Synthesis and biological evaluation of novel delta (δ) opioid receptor ligands with diazatricyclodecane skeletons.
AID149405Binding affinity was measured against Opioid receptor delta 1 using [3H]p-Cl-DPDPE as radioligand.1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor.
AID231538Ratio of binding affinity towards kappa opioid receptor by displacement of [3H]-U-69,593 radioligand to that of delta opioid receptor by displacement of [3H]-DADLE radioligand2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity.
AID1137711Displacement of [3H]DPDPE from delta opioid receptor in mouse whole brain cerebellum membrane2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID231647Binding affinity ratio on mu opioid receptor( rat brain membranes) with respect to delta opioid receptor (rat brain membranes)1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
AID1137713Selectivity ratio of Ki for mouse mu opioid receptor to Ki for mouse delta opioid receptor2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Novel delta opioid receptor agonists with oxazatricyclodecane structure.
AID148086Binding affinity was measured against mutated human Opioid receptor delta 1 (W248L)1998Journal of medicinal chemistry, Nov-19, Volume: 41, Issue:24
De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor.
AID231107Ratio of binding affinities (Mu/Delta)1999Bioorganic & medicinal chemistry letters, Oct-18, Volume: 9, Issue:20
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.
AID152374Affinity of [3H]DAMGO to the mu opioid receptor from rat brain2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID95359Binding affinity towards opioid kappa receptor using [3H]U-69593 as radioligand1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.
AID149613Agonistic activity towards opioid receptor delta 1 was determined in [35S]GTP-gamma-S, binding assay in guinea pig caudate2004Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
AID148533In vitro agonist activity for Opioid receptor delta 1 was determined in a mouse vas deferens assay1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective delta opioid agonists, based on an extension of the message-address concept.
AID386574Agonist activity at human delta opioid receptor in CHO cells assessed as stimulation of [35S]GTPgammaS binding2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
AID450628Agonist activity at delta opioid receptor expressed in HEK293 cells assessed as phosphorylation of MAP kinase at 10 uM after 10 mins by Western blot analysis2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID444094Agonist activity at human delta opioid receptor by [35S]GTPgammaS binding assay relative to SNC802009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent models.
AID1574665Displacement of [3H]DPDPE from DOR in Sprague-Dawley rat brain membranes after 120 mins by scintillation counting method2019Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2
Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation.
AID149729Agonist activity was evaluated in guinea pig ileum (GPI) preparations at Opioid receptor mu 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80)
AID148549Ability to stimulate binding to kappa-opioid receptor using GTP-gamma -S-binding assay in guinea pig caudate membranes, blocked with 6 nM nor-binaltorphimine (nor-BNI)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
AID148562Binding affinity towards Opioid receptor kappa 1 using [3H]- U-69,593 (1.5 nM) as radioligand in guinea pig brain membranes1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using AlCl3-promoted aminolysis.
AID87096Potency in the Hamster vas deferens (HVD) functional assay was determined in vivo1999Bioorganic & medicinal chemistry letters, May-03, Volume: 9, Issue:9
Synthesis of novel analogues of the delta opioid ligand SNC-80 using AlCl3-promoted aminolysis.
AID56303Agonistic activity towards Opioid receptor delta 1 as inhibitory activity towards electrically stimulated mouse vas deferens1996Journal of medicinal chemistry, May-10, Volume: 39, Issue:10
Probes for narcotic receptor-mediated phenomena. 21. Novel derivatives of 3-(1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-b]indol- 6-yl)-phenols with improved delta opioid receptor selectivity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346361Human delta receptor (Opioid receptors)1997European journal of pharmacology, May-12, Volume: 326, Issue:1
Relative efficacies of delta-opioid receptor agonists at the cloned human delta-opioid receptor.
AID1346361Human delta receptor (Opioid receptors)1994Journal of medicinal chemistry, Jul-08, Volume: 37, Issue:14
Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (275)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's39 (14.18)18.2507
2000's142 (51.64)29.6817
2010's73 (26.55)24.3611
2020's21 (7.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.99 (24.57)
Research Supply Index5.63 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (1.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other276 (98.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]